The present invention relates to a device and method for correcting mitral valve insufficiency, and more particularly, to a device capable of restoring valve leaflet coaptation Mitral regurgitation (MR) - also referred to as mitral insufficiency or mitral incompetence - is a common disorder caused by insufficient closure (coaptation) of the mitral valve leaflets when the left ventricle contracts. This leads to abnormal leaking of blood backwards from the left ventricle, through the mitral valve and into the left atrium. In the western world, MR is most commonly due to degenerative disease caused by morphological or functional changes to the leaflets, the valve annulus (which forms a ring around the valve leaflets), the papillary muscles and/or the chordae tendineae (which connect the valve leaflets to the papillary muscles). Morphological changes are classified under Degenerative Mitral Regurgitation (DMR) while functional changes are classified under functional mitral regurgitation (FMR). Treatment of mitral valve regurgitation includes medication such as diuretics beta blockers, heart rhythm regulators and/or surgery for augmenting or replacing mitral valve function. Mitral valve augmentation is typically effected via implantation of a ring-like device at the valve annulus. The procedure, termed annuloplasty, reshapes the the mitral valve annulus to reestablish the physiological configuration and improve leaflet coaptation. Mitral valve repair can be achieved by ring implantation alone, however, cases involving leaflets with sever anomalies and/or chordate elongation or damage to papillary muscles oftentimes requires additional repair procedures. One such procedure utilizes artificial chords which are sutured between the papillary muscles in the left ventricle (LV) and the free margin of the valve leaflet in order to recover the coaptation line. However, left ventricle remodeling in the post-operative period might negatively affect early results and lead to recurrence of mitral regurgitation. In addition to LV remodeling, suturing of artificial chord to the papillary muscle can be difficult to perform since the surgeon has limited access through the valve, making surgery more complex and time consuming and since it is oftentimes difficult to determine the correct length of artificial chords needed. In addition, the papillary muscle might be damaged by the procedure risking rupture of suturing site. There is thus a need for, and it would be highly advantageous to have, a device for repairing mitral valve regurgitation devoid of the above limitations.
Dispositivo para cirurgia plástica da válvula mitral para ser implantado em indivíduos afetados por doenças cardíacas valvulares que causam estenose e/ou insuficiência; e uso do dispositivo para cirurgia plástica da válvula mitra
J. Zeitani
2020
Abstract
The present invention relates to a device and method for correcting mitral valve insufficiency, and more particularly, to a device capable of restoring valve leaflet coaptation Mitral regurgitation (MR) - also referred to as mitral insufficiency or mitral incompetence - is a common disorder caused by insufficient closure (coaptation) of the mitral valve leaflets when the left ventricle contracts. This leads to abnormal leaking of blood backwards from the left ventricle, through the mitral valve and into the left atrium. In the western world, MR is most commonly due to degenerative disease caused by morphological or functional changes to the leaflets, the valve annulus (which forms a ring around the valve leaflets), the papillary muscles and/or the chordae tendineae (which connect the valve leaflets to the papillary muscles). Morphological changes are classified under Degenerative Mitral Regurgitation (DMR) while functional changes are classified under functional mitral regurgitation (FMR). Treatment of mitral valve regurgitation includes medication such as diuretics beta blockers, heart rhythm regulators and/or surgery for augmenting or replacing mitral valve function. Mitral valve augmentation is typically effected via implantation of a ring-like device at the valve annulus. The procedure, termed annuloplasty, reshapes the the mitral valve annulus to reestablish the physiological configuration and improve leaflet coaptation. Mitral valve repair can be achieved by ring implantation alone, however, cases involving leaflets with sever anomalies and/or chordate elongation or damage to papillary muscles oftentimes requires additional repair procedures. One such procedure utilizes artificial chords which are sutured between the papillary muscles in the left ventricle (LV) and the free margin of the valve leaflet in order to recover the coaptation line. However, left ventricle remodeling in the post-operative period might negatively affect early results and lead to recurrence of mitral regurgitation. In addition to LV remodeling, suturing of artificial chord to the papillary muscle can be difficult to perform since the surgeon has limited access through the valve, making surgery more complex and time consuming and since it is oftentimes difficult to determine the correct length of artificial chords needed. In addition, the papillary muscle might be damaged by the procedure risking rupture of suturing site. There is thus a need for, and it would be highly advantageous to have, a device for repairing mitral valve regurgitation devoid of the above limitations.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
